AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2356-2366

  Bush, Tammy L ^a   Payton, Marc ^a   Heller, Scott ^a   Chung, Grace ^a   Hanestad, Kelly ^a   Rottman, James B ^a   Loberg, Robert ^a   Friberg, Gregory ^a   Kendall, Richard L ^a   Saffran, Douglas ^a   Radinsky, Robert ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 900; ANTINEOPLASTIC AGENT; AURORA B KINASE; AURORA KINASE INHIBITOR; DOCETAXEL; HISTONE H3; IXABEPILONE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST METASTASIS; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AURORA KINASES; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM METASTASIS; PACLITAXEL; PHOSPHORYLATION; PHTHALAZINES; POLYPLOIDY; PROTEIN KINASE INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887420572     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36.
2. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14:1639-48.
3. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41.
4. Sorlie T, Perou CM, Tibshirani R, Aasf T, Geislerg S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001;98:10869-74.
5. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12: 1-18.
6. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010;15:49-56.
7. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005;65:4059-66.
8. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 2008;68:767-77.
9. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
10. Loddo M, Kingsbury SR, Rashid M, Proctor I, Holt C, Young J, et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. British J Cancer 2009;100:959-70.
11. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003;3:51-62.
12. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Disc 2010;9:790-803.
13. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:1-10.
14. McGrogana BT, Gilmartina B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008;1785:96-132.
15. Lee FYF, Borzilleri R, Fairchild CR, Soong-Hoon K, Long BH, Reventos- Suarez C, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.Clin Cancer Res 2001;7:1429-37.
16. Lee FYF, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008;63:157-66.
17. Mahadevan D, Stejskal A, Cooke LS, Manziello A, Morales C, Persky DO, et al. Aurora Ainhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-hodgkin lymphoma. Clin Cancer Res 2012;18:2210-9.
18. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70:9846-54.
19. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
20. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T, et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-88.
21. Freeman DJ, Bush TL, Ogbagabriel S, Belmontes B, Juan T, Plewa C, et al. Activity of Panitumumabalone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptors. Mol Cancer Ther 2009;8:1536-46.
22. Zhenfeng D, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-38.
23. Lincke CR, Smit JJ, van der Velde-Koerts T, Borst P. Structure of the human MDR3 gene and physical mapping of the human MDR locus. J Biol Chem 1991;266:5303-10.
24. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovicet L, Sikic BI. Resistance mechanisms in human sarcoma mutants derived by singlestep exposure to paclitaxel. Cancer Res 1996;56:1091-97.
25. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-66.
26. Dumontet C, Jordan MA, Lee FFY. Ixabepilone: targeting BIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009;8: 17-24.
27. Hernandez-Vargas H, Palacios J, Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 2007;26:2902-13.
28. Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM. MLN8054, an inhibitor of aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010;8:373-84.
29. Ganem N, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009;460:278-83.
30. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011;12:1-8.
31. Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Diff 2008;15:1153-62.
32. Borresen-Dale AL. TP53 and breast cancer. Human Mutation 2003;21: 292-300.
33. Jackson J, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D, et al. p53-Mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012;21: 793-806.
34. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
35. Szákacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Disc 2006;5:219-34.
36. Lee FYF, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008;14: 8123-31.
37. Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, et al. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol Cancer Ther 2012;11: 2693-703.
38. Rottenberg S, Vollebergh MA, de Hoon D, de Ronde J, Schouten PC, Kersbergen A, et al. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res Cancer Res 2012;72:2350-61.